Vistagen Therapeutics logo

Vistagen Therapeutics share price today

(VTGN)

Vistagen Therapeutics share price is $3.21 & ₹275.45 as on 7 Jan 2025, 2.30 'hrs' IST

$3.21

-0.13

(-3.89%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Vistagen Therapeutics share price in Dollar and Rupees. Guide to invest in Vistagen Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Vistagen Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Vistagen Therapeutics share price movements

  • Today's Low: $3.19
    Today's High: $3.37

    Day's Volatility :5.45%

  • 52 Weeks Low: $2.22
    52 Weeks High: $5.86

    52 Weeks Volatility :62.12%

Vistagen Therapeutics Returns

PeriodVistagen Therapeutics IncIndex (Russel 2000)
3 Months
13.61%
0.0%
6 Months
-6.96%
0.0%
1 Year
-38.83%
0.0%
3 Years
-93.78%
-19.8%

Vistagen Therapeutics Key Statistics

in dollars & INR

Previous Close
$3.34
Open
$3.3
Today's High
$3.374
Today's Low
$3.19
Market Capitalization
$82.1M
Today's Volume
$497.9K
52 Week High
$5.86
52 Week Low
$2.22
Revenue TTM
$876.3K
EBITDA
$-45.5M
Earnings Per Share (EPS)
$-0.74
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-61.52%

How to invest in Vistagen Therapeutics from India?

It is very easy for Indian residents to invest directly in Vistagen Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vistagen Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Vistagen Therapeutics or VTGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vistagen Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vistagen Therapeutics shares which would translate to 0.267 fractional shares of Vistagen Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Vistagen Therapeutics, in just a few clicks!

Returns in Vistagen Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vistagen Therapeutics investment value today

Current value as on today

₹62,014

Returns

₹37,986

(-37.99%)

Returns from Vistagen Therapeutics Stock

₹41,209 (-41.21%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Vistagen Therapeutics

25%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Vistagen Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 25% more investors are searching Vistagen Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Vistagen Therapeutics

  • TCG Crossover Management, LLC

    9.61%

  • Bvf Inc

    7.18%

  • StemPoint Capital LP

    6.63%

  • Vanguard Group Inc

    6.44%

  • COMMODORE CAPITAL LP

    5.66%

  • Nantahala Capital Management, LLC

    5.45%

Analyst Recommendation on Vistagen Therapeutics

Buy

    90%Buy

    10%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Vistagen Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Vistagen Therapeutics

What analysts predicted

Upside of 304.98%

Current:

$3.21

Target:

$13.00

Insights on Vistagen Therapeutics

  • Price Movement

    In the last 7 days, VTGN stock has moved up by 18.9%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 84.0K → 183.0K (in $), with an average increase of 54.1% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -6.34M → -12.96M (in $), with an average decrease of 27.8% per quarter
  • VTGN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 57.4%
  • VTGN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 149.1%
  • Price to Sales

    ForVTGN every $1 of sales, investors are willing to pay $115.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Vistagen Therapeutics Technicals Summary

Sell

Neutral

Buy

Vistagen Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Vistagen Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vistagen Therapeutics Inc
28.96%
-6.96%
-38.83%
-93.78%
-83.97%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vistagen Therapeutics Inc
NA
NA
0.0
-1.82
-0.62
-0.39
NA
3.44
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vistagen Therapeutics Inc
Buy
$82.1M
-83.97%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Vistagen Therapeutics

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Organization
Vistagen Therapeutics
Employees
39
CEO
Mr. Shawn K. Singh J.D.
Industry
Health Technology

Management People of Vistagen Therapeutics

NameTitle
Mr. Shawn K. Singh J.D.
CEO & Director
Ms. Cynthia Lynn Anderson CPA
VP & Chief Financial Officer
Mr. Joshua S. Prince M.B.A.
Chief Operating Officer
Mr. Reid G. Adler Esq., J.D.
Chief Corporate Development Officer & General Counsel
Mr. Mark Adrian McPartland
Senior Vice President of Investor Relations
Ms. Trisha Fitzmaurice
Senior Vice President of Human Resources
Dr. Allen Easley Cato III, M.D., Ph.D.
Senior Vice President of Development Operations
Dr. Mark J. Ginski Ph.D.
Senior VP and Head of Chemistry, Manufacturing & Controls
Mr. Mark Flather
Senior Vice President of Corporate Strategy & Capital Markets
Dr. Erik Berglund M.D., Ph.D.
Senior Vice President of Global Regulatory Affairs & Pharmacovigilance

Important FAQs about investing in Vistagen Therapeutics from India :

What is Vistagen Therapeutics share price today?

Vistagen Therapeutics share price today stands at $3.21, Open: $3.30 ; Previous Close: $3.34 ; High: $3.37 ; Low: $3.19 ; 52 Week High: $5.86 ; 52 Week Low: $2.22. The stock opens at $3.30, after a previous close of $3.34. The stock reached a daily high of $3.37 and a low of $3.19, with a 52-week high of $5.86 and a 52-week low of $2.22.

Can Indians buy Vistagen Therapeutics shares?

Yes, Indians can invest in the Vistagen Therapeutics (VTGN) from India.

With INDmoney, you can buy Vistagen Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Vistagen Therapeutics at zero transaction cost.

How can I buy Vistagen Therapeutics shares from India?

It is very easy to buy Vistagen Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vistagen Therapeutics be purchased?

Yes, you can buy fractional shares of Vistagen Therapeutics with INDmoney app.

What are the documents required to start investing in Vistagen Therapeutics stocks?

To start investing in Vistagen Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Vistagen Therapeutics

Today’s highest price of Vistagen Therapeutics (VTGN) is $3.37.

Today’s lowest price of Vistagen Therapeutics (VTGN) is $3.19.

What is today's market capitalisation of Vistagen Therapeutics

Today's market capitalisation of Vistagen Therapeutics VTGN is 82.1M

What is the 52 Week High and Low Range of Vistagen Therapeutics

  • 52 Week High

    $5.86

  • 52 Week Low

    $2.22

What are the historical returns of Vistagen Therapeutics?

  • 1 Month Returns

    28.96%

  • 3 Months Returns

    -6.96%

  • 1 Year Returns

    -38.83%

  • 5 Years Returns

    -83.97%

Who is the Chief Executive Officer (CEO) of Vistagen Therapeutics

Mr. Shawn K. Singh J.D. is the current Chief Executive Officer (CEO) of Vistagen Therapeutics.